



DEVONIAN HEALTH GROUP INC.

Interim Condensed Consolidated Financial Statements for the three months and six months ended:

January 31, 2026, and 2025

(Unaudited)

Devonian Health Group Inc.

Interim Condensed Consolidated Statements of Financial Position

As at January 31, 2026 and July 31, 2025

(Unaudited)

	January 31, 2026 \$	July 31, 2025 \$
Assets		
Current assets		
Cash and cash equivalents	1,292,337	6,983,620
Accounts receivable (note 4)	567,564	1,133,759
Tax credits receivable	222,745	368,994
Deferred financing charges	138,158	-
Inventories	14,850	34,513
Prepaid expenses	238,775	203,404
	<u>2,474,429</u>	<u>8,724,290</u>
Property, plant, equipment, and right-of-use assets	2,191,108	2,203,143
Intangible assets	<u>4,901,338</u>	<u>4,902,870</u>
	<u>9,566,875</u>	<u>15,830,303</u>
Liabilities		
Current liabilities		
Accounts payable (note 5)	1,509,098	6,533,602
Income tax liability	-	33,229
Current portion of lease liability	79,478	47,648
	<u>1,588,576</u>	<u>6,614,479</u>
Lease liability	<u>79,001</u>	<u>78,156</u>
	<u>1,667,577</u>	<u>6,692,635</u>
Shareholders' Equity		
Share capital (note 6)	31,399,122	30,438,321
Stock options (note 7)	3,201,262	2,663,081
Warrants (note 8)	1,243,167	371,487
Contributed surplus	9,119,808	8,930,758
Deficit	(37,064,061)	(33,265,979)
	<u>7,899,298</u>	<u>9,137,668</u>
	<u>9,566,875</u>	<u>15,830,303</u>

Approved by the Board of Directors

(s) Pierre Labbé, Director (s) André Boulet, Director

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Devonian Health Group Inc.

Interim Condensed Consolidated Statements of Net Loss and Comprehensive Loss

For the three-month and six-month periods ended January 31, 2026 and 2025

(Unaudited)

	Three months ended January 31		Six months ended January 31	
	2026	2025	2026	2025
	\$	\$	\$	\$
Distribution revenues	487,824	8,827,629	1,540,067	14,948,410
Cost of sales (note 3)	454,518	6,214,669	976,649	10,359,243
Gross margin	33,306	2,612,960	563,418	4,589,167
Operating expenses				
Research and development expenses	381,667	574,720	841,938	1,068,851
Selling and administrative expenses	1,897,946	1,795,570	3,561,595	3,846,794
Financial expenses (note 9)	4,646	99,207	8,559	225,102
Income (loss) from operations	(2,250,953)	143,463	(3,848,674)	(551,580)
Interest income	11,999	65,832	50,592	154,209
Net income (loss) and comprehensive loss before income tax	(2,238,954)	209,295	(3,798,082)	(397,371)
Income tax expense	-	437,054	-	437,054
Net loss and comprehensive loss (note 1)	(2,238,954)	(227,759)	(3,798,082)	(834,425)
Net loss per share (note 10)				
Basic and diluted	(0.81)	(0.09)	(1.37)	(0.36)

Additional information to the interim condensed consolidated statements of net loss and comprehensive loss
(notes 1, 3 and 10)

Current and prior period number of outstanding shares and options amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on January 22, 2026. See Note 1(b) for details.

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Devonian Health Group Inc.

Interim Condensed Consolidated Statement of Changes of Equity

For the six-month periods ended January 31, 2026 and 2025

(Unaudited)

	Number of				Amount						
	Shares	Shares to be issued	Stock options	Warrants	Share capital	Shares to be issued	Stock options	Warrants	Contributed surplus	Deficit	Total
					\$	\$	\$	\$	\$	\$	\$
For the six months ended January 31, 2025											
Balance as at July 31, 2024	2,470,376	-	276,462	12,941,850	29,838,321	-	2,071,861	862,261	8,340,731	(27,253,188)	13,859,986
Stock-based compensation	-	-	80,571	-	-	-	610,833	-	-	-	610,833
Stock options canceled	-	-	(13,893)	-	-	-	(99,253)	-	99,253	-	-
Warrants expired	-	-	-	(201,982)	-	-	-	(20,274)	20,274	-	-
Net loss and comprehensive loss for the period	-	-	-	-	-	-	-	-	-	(834,425)	(834,425)
	-	-	66,678	(201,982)	-	-	511,580	(20,274)	119,527	(834,425)	(223,592)
Balance as at January 31, 2025	2,470,376	-	343,140	12,739,868	29,838,321	-	2,583,441	841,987	8,460,258	(28,087,613)	13,636,394
For the six months ended January 31, 2026											
Balance as at July 31, 2025	2,470,376	66,667	364,615	4,339,770	29,838,321	600,000	2,663,081	371,487	8,930,758	(33,265,979)	9,137,668
Subscription of units	-	(66,667)	-	-	-	(600,000)	-	-	-	-	(600,000)
Issuance of shares (note 6)	295,353	-	-	-	1,605,570	-	-	-	-	-	1,605,570
Stock-based compensation (note 7)	-	-	57,225	-	-	-	538,181	-	-	-	538,181
Issuance of warrants (note 8)	-	-	-	17,720,981	-	-	-	1,091,930	-	-	1,091,930
Cash shares issuance costs	-	-	-	-	(44,769)	-	-	(31,200)	-	-	(75,969)
Warrants expired (note 8)	-	-	-	(2,452,007)	-	-	-	(189,050)	189,050	-	-
Net loss and comprehensive loss for the period	-	-	-	-	-	-	-	-	-	(3,798,082)	(3,798,082)
	295,353	(66,667)	57,225	15,268,974	1,560,801	(600,000)	538,181	871,680	189,050	(3,798,082)	(1,238,370)
Balance, as at January 31, 2026	2,765,729	-	421,840	19,608,744	31,399,122	-	3,201,262	1,243,167	9,119,808	(37,064,061)	7,899,298

Current and prior period share and options amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on January 22, 2026. See Note 1 (b) Reverse Stock Split, for details.

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Devonian Health Group Inc.

Interim Condensed Consolidated Statement of Cash Flows

For the six-month periods ended January 31, 2026 and 2025

(Unaudited)

	Six months ended January 31, 2026 \$	Six months ended January 31, 2020 \$
Cash flows from		
Operating activities		
Net loss	(3,798,082)	(834,425)
Items not affecting cash:		
Amortization of property, plant, equipment, and right-of-use asset	74,857	155,494
Amortization of intangible assets	1,532	23,230
Amortization of deferred financial fees	-	84,383
Interest on lease liability	4,344	-
Stock-based compensation	538,181	610,833
	(3,179,168)	39,515
Net change in non-cash working capital items (note 11)	(4,499,156)	721,008
<i>Cash provided by (used in) operating activities</i>	(7,678,324)	760,523
Investing activities		
Acquisition of property, plant, and equipment	(6,500)	(17,350)
	(6,500)	(17,350)
<i>Cash used in investing activities</i>	(6,500)	(17,350)
Financing activities		
Principal payments on lease liability	(27,990)	(21,929)
Issuance of shares and warrants, net of issuance costs (note 6, 8)	2,021,531	-
Repayment of long-term debt	-	(2,160,000)
<i>Cash provided by (used in) financing activities</i>	1,993,541	(2,181,929)
Increase (decrease) in cash	(5,691,283)	(1,438,756)
Cash and cash equivalents – Beginning of period	6,983,620	9,862,511
Cash and cash equivalents – End of period	1,292,337	8,423,755

For the period ended January 31, 2026, cash flow from operating activities includes interest paid of nil (2025 - \$129,201).

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

1 (a) Statutes of incorporation, nature of activities and material uncertainty related to going concern

Devonian Health Group Inc. ("Devonian" or the "Company") was incorporated under the *Business Corporations Act* (Québec) on March 27, 2015. On May 12, 2017, the Company was continued under the *Canada Business Corporations Act*.

On December 31, 2024, following a corporate reorganization, Altius Healthcare Inc, the former fully owned subsidiary of Devonian, transferred all its assets and liabilities to Altius Healthcare Group L.P. ("Altius"), a limited partnership where Devonian is the ultimate holder of 100% of the units. Altius Healthcare Inc, merged with Devonian Health Group Inc. the same day.

Devonian's main activity is the development of drugs for auto-immune inflammatory conditions. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through Altius. The Company has established a research effort focused on new solutions in the medical field as well as in the cosmetic field. The Company's head office is located at 360, rue des Entrepreneurs, Montmagny, Quebec.

These interim condensed consolidated financial statements (the "consolidated financial statements") have been prepared on a going concern basis, which assumes that assets will be realized, and liabilities discharged in the normal course of business for the foreseeable future. Accordingly, these interim condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or on the discharge or classification of liabilities, should the Company be unable to continue its normal course of business. The company is engaged in the development of botanical drugs and will need to obtain necessary financing to continue its operations until the commercialization phase of its products. For the six- month periods ended January 31, 2026, the Company incurred net losses from operations of \$3,798,082 (2025 - \$834,425) resulting in an accumulated deficit of \$37,064,061 as at January 31, 2026 (July 31, 2025 - \$33,265,979). The Company's liquidities are limited considering its ongoing projects and the non-renewal of its distribution contracts for Dextansoprazole and Pantoprazole magnesium which will materially affect the Company's cashflows from operations.

Consequently, the Company's ability to continue as a going concern depends on its ability to obtain further financing in a timely manner in order to complete research and development projects, and to market its developed products.

Management continues to explore further financing and different agreements that could create positive cash flows. The success of these discussions is contingent on many factors outside of the Company's control, and its ability to successfully complete such financings and agreements raises substantial doubt about the Company's ability to continue as a going concern.

These interim condensed consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statement of financial classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities in the normal course of operations. Such adjustments could be material.

(b) Reverse Stock Split

Devonian completed a one for sixty (1-for-60) reverse stock split of its common stock on January 22, 2026 (the "Reverse Split"). Accordingly, all shareholders of record at the opening of business on January 22, 2026, received one issued and outstanding common share of Devonian in exchange for 60 outstanding common shares of the Company. No fractional shares were issued in connection with the Reverse Split. All fractional

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

shares created by the Reverse Split were rounded to the nearest whole number of common shares, with any fractional interest representing 0.5 or more common shares entitling holders thereof to receive one whole common share.

Effective on the date of the Reverse Split, the exercise price and number of common shares issuable upon the exercise of outstanding stock options were proportionately adjusted to reflect the Reverse Split. While the number of warrants has not changed as a result of the Reverse Split, the conversion rate for each warrant was adjusted from one common share to 0.01667 common share. All information relating to outstanding common shares, stock options and warrants as well as net loss per share, in the current and comparative periods presented herein give effect to the Reverse Split.

2 Material accounting policies

Declaration of compliance

These interim condensed consolidated financial statements have been prepared in accordance with *International Accounting Standard 34*, Interim Financial Reporting. As a result, certain information and notes normally included in annual financial statements prepared in accordance with IFRS, as published by IASB, have been omitted or summarized. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements for the years ended July 31, 2025, and 2024.

These interim condensed consolidated financial statements were approved by the board of directors on March 24, 2026.

Significant accounting policies

These interim condensed consolidated financial statements were based on the material accounting policies described in the Company's consolidated financial statements for the year ended July 31, 2025 and 2024.

Use of estimates and judgments

The preparation of these interim condensed consolidated financial statements required management to use judgment, make estimates and make assumptions that affect the application of accounting policies and the carrying value of assets, liabilities, revenues and expenses. Actual results could differ from estimated results. Significant accounting judgments and estimates applied by the Company are presented in the consolidated financial statements for the years ended July 31, 2025 and 2024 and remain unchanged. Estimates and underlying assumptions are reviewed regularly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected by such revisions.

3 Additional information to the interim condensed consolidated statements of net loss and comprehensive loss

The interim-condensed consolidated statements of net loss and comprehensive loss include the following items for the three-month periods ended:

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

	Three months ended January 31	
	2026	2025
	\$	\$
Research and development expenses – Amortization of property, plant and equipment and right-of-use assets	37,459	77,964
Selling and administrative expenses – Salaries and employer's contributions	478,282	(259,436)
Selling and administrative expenses – Stock-based compensation	538,181	215,000
Research and development expenses – Salaries and employer's contributions	80,531	155,292
Cost of sales – Profit sharing & royalties	61,940	906,038
Cost of sales – Cost of inventories	283,588	5,249,808
Cost of sales – Logistic expenses	108,224	47,206
Cost of sales – Amortization of intangible assets	766	11,615

The interim-condensed consolidated statements of net loss and comprehensive loss include the following items for the six-month periods ended:

	Six months ended January 31	
	2026	2025
	\$	\$
Research and development expenses – Amortization of property, plant and equipment and right-of-use assets	74,857	155,494
Selling and administrative expenses – Salaries and employer's contributions	1,152,002	156,847
Selling and administrative expenses – Stock-based compensation	538,181	610,833
Research and development expenses – Salaries and employer's contributions	168,011	284,622
Cost of sales – Profit sharing & royalties	165,389	2,071,222
Cost of sales – Cost of inventories	667,479	8,138,341
Cost of sales – Logistic expenses	142,249	126,449
Cost of sales – Amortization of intangible assets	1,532	23,230

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

4 Accounts receivable

	January 31, 2021 \$	July 31, 2020 \$
Trade	465,574	475,884
Sales taxes	93,022	579,392
Interest receivable	8,968	78,483
	<u>567,564</u>	<u>1,133,759</u>

5 Accounts payable

	January 31, 2021 \$	July 31, 2020 \$
Suppliers	690,766	4,356,518
Accrued expenses	657,326	2,079,154
Salaries, payroll deductions and contributions	161,006	97,930
	<u>1,509,098</u>	<u>6,533,602</u>

6 Share capital

As disclosed in note 1(b) the 1-for-60 Reverse Split effective on January 22, 2026, has been applied retrospectively herein.

Description of authorized share capital

Unlimited common shares without nominal or par value.

	January 31, 2021 \$	July 31, 2020 \$
Share capital issued and subscribed		
2,765,729 common shares (July 31, 2025 – 2,470,376)	31,399,122	29,838,321
Nil common shares subscribed (July 31, 2025 – 66,667)	-	600,000
	<u>31,399,122</u>	<u>30,438,321</u>

On August 7, 2025, the Company completed a private placement by issuing 262,559 units at a price of \$9.00 per unit for gross proceeds of \$2,363,000. Each unit consists of one common share and sixty share purchase warrants. Each warrant allows its holder to acquire 1/60 common share, at a price of \$0.20 (60 warrants for one common share), until August 7, 2027.

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

The related issuance costs of \$43,366 were proportionately split between share capital and warrants and recognized as a reduction in their respective initial value.

The fair value of the 262,559 shares issued was estimated at \$1,386,235 using the residual method. The fair value of the 15,753,332 warrants issued was estimated at \$933,399 using the Black-Scholes valuation model and the following assumptions:

Risk-free interest rate	3.75%
Average expected duration	2 years
Expected volatility	149%
1/60 of share price	\$0.15
Expected dividend	\$nil

On October 22, 2025, the Company completed a non-brokered private placement for aggregate gross proceeds of \$334,500. The Offering consisted of the issuance of 32,794 units of the Corporation at a price of \$10.20 per Unit. Each Unit consists of one common share of the Corporation and sixty Share purchase warrants. Each Warrant entitles the holder thereof to purchase 1/60 common Share at an exercise price of \$0.17 (60 warrants for one common share) for a period of 24 months from the date of issuance thereof.

The related issuance costs of \$32,603 were proportionately split between share capital and warrants and recognized as a reduction in their respective initial value.

The fair value of the 32,794 shares issued was estimated at \$174,566 using the residual method. The fair value of the 1,967,649 warrants issued was estimated at \$127,331 using the Black-Scholes valuation model and the following assumptions:

Risk-free interest rate	3.56%
Average expected duration	2 years
Expected volatility	153%
1/60 of share price	\$0.17
Expected dividend	\$nil

7 Stock option plan

On December 19, 2025, the Company granted 57,225 stock options of at an exercise price of \$11.40 for a period of ten years from the grant date. Of those options, 46,629 were granted to independent directors of the Company and 2,500 to a consultant and are exercisable on the grant date.

Of the remaining 8,096 options, 6,430 were granted to employees of the Company (of which 684 were granted to an officer of the Company) and 1,666 were granted to a research and development consultant. 2,024 of these 8,096 options are exercisable on the grant date while the other 6,072 vest in equal instalments over a period of 3 years at the grant anniversary date.

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

The fair value of these stock options was estimated at \$602,064 based on the Black Scholes valuation model and using the following assumptions:

Risk-free interest rate	3.89%
Average expected duration	5 years
Expected volatility	154%
1/60 of share price	\$0.19
Expected dividend	\$nil

The following table summarizes the situation of the Company's Stock Option Plan and the changes incurred during the six-month period ended January 31, 2026, and for the twelve-month period ended July 31, 2025.

	Six months ended January 31, 2021		Twelve months ended July 31, 2025	
	Number	Weighted average exercise price \$	Number	Weighted average exercise price \$
Outstanding – Beginning of the period	364,615	13.89	276,462	15.60
Options expired	-		(13,893)	12.92
Options granted to directors and members of management	47,313	11.40	96,213	10.20
Options granted to employees and consultants	9,912	11.40	5,833	9.00
Outstanding – End of the period	421,840	13.55	364,615	13.89
Options exercisable – End of the period	390,937	13.25	339,784	13.53
Weighted average fair value of the options granted during the period		10.52		7.20

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

The following table summarizes information about the options outstanding and exercisable as at January 31, 2026:

Exercise price \$	Number of options outstanding	Number of options exercisable	Weighted average remaining contractual life January 31, 2026
7.20	12,527	12,527	4.91 years
7.50	62,758	62,758	7.84 years
8.70	8,333	5,833	8.35 years
9.00	94,771	84,105	7.53 years
9.60	54,975	54,975	8.69 years
11.40	82,820	76,748	9.63 years
12.00	13,082	13,082	7.12 years
12.60	11,248	11,248	4.51 years
20.40	833	833	6.94 years
24.00	15,329	15,329	5.80 years
30.00	45,000	33,335	5.90 years
36.00	20,164	20,164	2.44 years
	<u>421,840</u>	<u>390,937</u>	

8 Warrants

The following table summarizes information about the Company's warrants and the changes during the six-month period ended January 31, 2026, and the twelve-month period ended July 31, 2025, all of which are exercisable:

	Six months ended January 31, 2021		Twelve months ended July 31, 2020	
	Number	Weighted average exercise price \$	Number	Weighted average exercise price \$
Outstanding, beginning of period	4,339,770	0,30	12,941,850	0,24
Issued	17,720,981	0,20	-	-
Expired	(2,452,007)	0,31	(8,602,080)	0,20
Outstanding, end of period	<u>19,608,744</u>	<u>0,19</u>	<u>4,339,770</u>	<u>0,30</u>

The issuance of warrants in the six-month period ended January 31, 2026 is related to the private placements described in Note 6. As a result of the Reverse Split, as disclosed in note 1(b), the warrant holder must exercise 60 warrants to receive one common share.

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

The following table summarizes information about outstanding warrants as at January 31, 2026 and July 31, 2025:

Warrants outstanding as at January 31, 2026		
Exercise price	Number of warrants outstanding	Average remaining contractual life
\$		
0.17 to 0.20	19,212,979	0.11 to 1.73 years
0.52 to 0.69	355,766	0.01 to 1.16 years
0.95	39,999	0.62 year
	<u>19,608,744</u>	
Warrants outstanding as at July 31, 2025		
Exercise price	Number of warrants outstanding	Average remaining contractual life
\$		
0.20 – 0.28	3,764,727	0.08 – 0.62 years
0.52 – 0.69	535,044	0.01 – 1.67 years
0.95	39,999	1.13 year
	<u>4,339,770</u>	

9 Financial expenses

Financial expenses are as follows, for the three-month and six-month periods ended:

	Three months ended		Six months ended	
	January 31		January 31	
	2026	2025	2026	2025
	\$	\$	\$	\$
Interest expenses and bank charges	2,162	3,552	4,215	6,562
Interest on long-term debt	-	45,065	-	129,201
Interest on lease liability	2,484	2,371	4,344	4,956
Amortization of deferred financial fees		48,219	-	84,383
	<u>4,646</u>	<u>99,207</u>	<u>8,559</u>	<u>225,102</u>

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

10 Net loss and comprehensive loss per share

The following table provides the weighted average number of shares used to calculate the basic loss per share for the three-month and six-month periods ended:

	Three months ended January 31		Six months ended January 31	
	2026	2025	2026	2025
Weighted average number of shares used to calculate the basic loss per share	2,765,729	2,470,376	2,764,659	2,470,376
Items excluded from the calculation of diluted loss per share:				
Stock options	421,840	343,140	421,840	343,140
Warrants (60 warrants for one share)	326,812	212,331	326,812	212,331

For the three-month and six-month periods ended, January 31, 2026, and 2025, the impacts of the warrants and stock options were excluded from the calculation of diluted loss per share as they would have an anti-dilutive effect.

11 Details of consolidated statements of cash flows

Changes in non-cash working capital

The changes in non-cash working capital items for the six-month periods ended January 31, 2026, and 2025 July 31, 2021 and 2020 are as follows:

	Six months ended January 31	
	2026	2025
	\$	\$
Accounts receivable	566,195	492,284
Tax credits receivable	146,249	-
Inventories	19,663	(43,132)
Prepaid expenses	(35,371)	(116,513)
Interest reserve	-	160,000
Deferred financing fees	(138,158)	-
Accounts payable	(5,024,505)	(665,883)
Income tax payable	(33,229)	894,252
	(4,499,156)	721,008

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

12 Related party transactions

The principal executives are the Chairman and CEO of the Company, the President of the subsidiary Altius, the Chief Financial Officer, the Executive Vice-President Strategy and the Directors. During the six-month period ended January 31, 2026, the Company has paid its principal executives a total remuneration of \$1,409,160 (2025 – \$1,496,610), which has been recognized in administrative expenses and of which the main components are:

	Six months ended January 31	
	2026	2025
	\$	\$
Included in selling and administrative expenses		
Salaries and benefits	502,677	815,177
Director fees	75,000	-
Severance	300,000	
Stock-based compensation (note 10)	497,733	610,833
	<u>1,375,410</u>	<u>1,426,010</u>
Included in research and development expenses		
Salaries and benefits	33,750	67,500
Consulting fees	-	3,100
	<u>33,750</u>	<u>70,600</u>
Included in accounts payable		
Accrued salaries and expense reimbursements	94,593	18,462
Consulting fees	42,841	-
	<u>137,434</u>	<u>18,462</u>

13 Segment information

The Company is currently operating in a single reportable operating segment in Canada, which is the pharmaceutical sector.

The following table details the disaggregation of distribution revenues during the financial periods:

	Three months ended January 31		Six months ended January 31	
	2026	2025	2026	2025
	\$	\$	\$	\$
Pantoprazole Magnesium	529,606	191,567	1 348,402	576,522
Cléo-35®	130,503	112,498	228,778	149,839
Dexlansoprazole	(172,285)	8,523,564	(37,113)	14,222,049
	<u>487,824</u>	<u>8,827,629</u>	<u>1,540,067</u>	<u>14,948,410</u>

Devonian Health Group Inc.

Notes to Interim Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

After the expiry of the distribution agreement for Dexlansoprazole in April 2025 the Company no longer has sales of the product. The Dexlansoprazole sales amounts recorded in the periods ended January 31, 2026, relate to true up of program allowance accruals and other similar charges presented as reduction of sales. Pantoprazole Magnesium distribution agreement will expire in April 2026. The Company expects to no longer sell Pantoprazole Magnesium after April 2026. Cléo-35 continues to be sold.

14 Economic dependence

During the three-month period ended January 31, 2026, the Company realized 37% (2025 – 37%) of its revenues from one client and 97% (2025 – 96%) of its purchases of inventories from one supplier.

During the six-month period ended January 31, 2026, the Company realized 37% (2025 – 40%) of its revenues from one client and 98% (2025 – 95%) of its purchases of inventories from one supplier.

15 Subsequent events

On February 2, 2026, the Company granted 25,000 stock options to an officer. Each option entitles the holder to purchase one common share at an exercise price of \$11.50, for a period of ten years from the grant date. Those options are exercisable on the grant date.

On February 11, 2026, the Company granted a total of 52,000 stock options to four consultants. Each option entitles the option holders to purchase one common share of the Company, at an exercise price of \$11.90. Those stock options are also exercisable on the grant date, and for a period of ten years.

On February 12, 2026, 333,334 warrants were exercised at a price of \$0.20 per warrant. As a result of the Reverse Split, as mentioned in the note 1 (b), the conversion rate for each warrant was adjusted from one common share to 0.01667 common share. Following the exercise of these 333,334 warrants, 5,555 common shares were issued.

On March 9, 2026, and March 13, 2026, 200,000 and 375,000 warrants were respectively exercised at a price of \$0.20 per warrant for total gross proceeds of \$115,000. As a result of the Reverse Split, as mentioned in the note 1 (b), the conversion rate for each warrant was adjusted from one common share to 0.01667 common share. Following the exercise of these warrants, 9,582 common shares were issued.